Results 241 to 250 of about 886,649 (291)

Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies. [PDF]

Am J Case Rep
Huang Z, Zhang Y, Chen J, Shi Y, Chen P, Jiang S, Qian H.   +6 more
europepmc   +1 more source

Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease. [PDF]

Ann Hematol
Zheng J, Zhou Y, Zhao Y, Luo Y, Yu J, Lai X, Wang J, Ye Y, Liu L, Fu H, Yang L, Wu Y, Sun J, Zheng W, He J, Zhao Y, Wu W, Cai Z, Wei G, Huang H, Li W, Shi J.   +21 more
europepmc   +1 more source

Philadelphia chromosome-positive acute myeloid leukemia successfully treated by allogeneic hematopoietic stem cell transplantation: A case report and review of the literature. [PDF]

Medicine (Baltimore)
Zhang Z, Wang X, Bai J, Yang X, Lian B, Zhang Y, Kang J, Pan Y.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

American journal of hematology/oncology, 2023
The combination of ponatinib, a third‐generation BCR::ABL1 tyrosine kinase inhibitor, with hyper‐CVAD chemotherapy resulted in high rates of complete molecular remissions and survival, without the need for stem cell transplantation (SCT) in most patients
H. Kantarjian, N. Short, N. Jain, K. Sasaki, Xuelin Huang, F. Haddad, I. Khouri, C. Dinardo, N. Pemmaraju, W. Wierda, G. Garcia-Manero, P. Kebriaei, Rebecca E. Garris, S. Loghavi, J. Jorgensen, M. Kwari, S. O'brien, F. Ravandi, E. Jabbour   +18 more
semanticscholar   +1 more source

Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.

JAMA Oncology, 2022
Importance With the advent of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs), Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now a relatively favorable-risk acute leukemia.
E. Jabbour, F. Haddad, N. Short, H. Kantarjian   +3 more
semanticscholar   +1 more source

Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

Cancer, 2021
The achievement of a 3‐month complete molecular response (CMR) is a major prognostic factor for survival in patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL).
K. Sasaki, H. Kantarjian, N. Short, Bachar Samra, J. Khoury, Rashmi Kanagal Shamanna, M. Konopleva, N. Jain, C. Dinardo, Rita Khouri, G. Garcia-Manero, T. Kadia, W. Wierda, I. Khouri, P. Kebriaei, R. Mehta, R. Champlin, Rebecca E. Garris, Cora Cheung, N. Daver, P. Thompson, M. Yilmaz, F. Ravandi, E. Jabbour   +23 more
semanticscholar   +1 more source

PHILADELPHIA CHROMOSOME BY TRANSLOCATION

The Lancet, 1973
SCOPUS: le.j ; info:eu-repo/semantics ...
Petit, Paul, Cauchie, Charles
openaire   +5 more sources

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Science, 1990
In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia chromosome, a fusion of chromosomes 9 and 22, directs the synthesis of the P210bcr/abl protein.
G. Daley, R. A. Etten, D. Baltimore
semanticscholar   +1 more source

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

, 2021
7001Background: Achievement of a complete molecular remission (CMR) is associated with superior outcomes in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
N. Short, H. Kantarjian, M. Konopleva, N. Jain, Xuelin Huang, F. Ravandi, W. Wierda, G. Borthakur, K. Sasaki, G. Issa, Y. Alvarado, N. Pemmaraju, G. Garcia-Manero, J. Thankachan, Rebecca E. Garris, E. Jabbour   +15 more
semanticscholar   +1 more source